You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK)遞交完全自主研發口服PD-L1小分子抑制劑ASC61美國臨牀試驗申請,用於治療晚期實體瘤
格隆匯 01-10 08:11

格隆匯1月10日丨歌禮制藥-B(01672.HK)發佈公吿,公司已遞交完全自主研發的口服PD-L1小分子抑制劑ASC61美國臨牀試驗申請(IND),用於治療晚期實體瘤。

根據披露,ASC61是一款強效、高選擇性的口服PD-L1小分子抑制劑,通過誘導PD-L1二聚體的形成和內吞,從而阻斷PD-1/PD-L1的相互作用。ASC61單藥在人源化小鼠模型等多種動物模型中表現出顯着的抗腫瘤療效。臨牀前研究顯示,ASC61在動物模型中有良好的安全性和藥代動力學特徵。用於臨牀試驗的ASC61口服片劑由公司專有製劑技術開發。

與PD-1/PD-L1抗體注射劑相比,口服PD-L1抑制劑ASC61具有以下優勢:(1)給藥方便,無需因注射用藥去醫院就診;(2)與其他口服抗腫瘤藥物聯用組成全口服治療方案;及(3)能夠及時調整給藥劑量,更好地管理免疫相關不良事件。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account